Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) Equity Average: 2018-2025

Historic Equity Average for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Sep 2025 value amounting to $227.8 million.

  • Arcturus Therapeutics Holdings' Equity Average fell 12.46% to $227.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.8 million, marking a year-over-year decrease of 12.46%. This contributed to the annual value of $259.7 million for FY2024, which is 5.34% down from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its Equity Average stood at $227.8 million for Q3 2025, which was down 1.98% from $232.4 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Equity Average ranged from a high of $374.6 million in Q1 2021 and a low of $158.2 million during Q3 2022.
  • Its 3-year average for Equity Average is $264.6 million, with a median of $261.3 million in 2024.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Equity Average spiked by 1,651.44% in 2021, and later slumped by 46.00% in 2022.
  • Quarterly analysis of 5 years shows Arcturus Therapeutics Holdings' Equity Average stood at $243.7 million in 2021, then declined by 14.64% to $208.0 million in 2022, then surged by 34.28% to $279.3 million in 2023, then fell by 9.98% to $251.4 million in 2024, then decreased by 12.46% to $227.8 million in 2025.
  • Its Equity Average was $227.8 million in Q3 2025, compared to $232.4 million in Q2 2025 and $237.4 million in Q1 2025.